Last reviewed · How we verify

Triamcinolone Acetonide + laser

Jaeb Center for Health Research · Phase 3 active Small molecule

Triamcinolone acetonide is a corticosteroid that reduces inflammation, combined with laser treatment to mechanically ablate or coagulate tissue, used together to treat retinal conditions.

Triamcinolone acetonide is a corticosteroid that reduces inflammation, combined with laser treatment to mechanically ablate or coagulate tissue, used together to treat retinal conditions. Used for Diabetic macular edema, Retinal vein occlusion with macular edema.

At a glance

Generic nameTriamcinolone Acetonide + laser
Also known ascorticosteroid
SponsorJaeb Center for Health Research
Drug classCorticosteroid + laser therapy combination
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Triamcinolone acetonide suppresses inflammatory cytokines and immune cell infiltration by binding glucocorticoid receptors, reducing edema and inflammation in the retina. Laser photocoagulation simultaneously provides thermal ablation or coagulation of abnormal retinal tissue. The combination approach addresses both the inflammatory component and structural pathology in retinal disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: